Compare
Cryoport, Inc. vs Phathom Pharmaceuticals, Inc. vs Lifevantage Corp vs Rhythm Pharmaceuticals, Inc.
| Latest fiscal year | Cryoport, Inc. CYRX | Phathom Pharmaceuticals, Inc. PHAT | Lifevantage Corp LFVN | Rhythm Pharmaceuticals, Inc. RYTM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $176.18M | $175.11M | $182.59M | $189.76M |
| Revenue growth (YoY) | +12.4% | +216.9% | -20.1% | +45.8% |
| Gross margin | 47.1% | 87.1% | 77.6% | 89.7% (computed) |
| Operating margin | -20.9% | -91.4% | 3.3% | -101.2% |
| Net margin | 44.4% | -126.3% | 2.8% | -103.6% |
| Net income | $78.30M | -$221.25M | $5.07M | -$196.54M |
| EPS (Diluted) | $1.40 | -$3.03 | $0.40 | -$3.11 |
| Operating cash flow | -$8.58M | -$166.78M | $10.24M | -$115.67M |
| Free cash flow | -$25.02M | -$167.00M | $6.67M | -$116.63M |
| Cash & equivalents | $250.49M | $129.97M | n/a | $54.30M |
| Total assets | $764.99M | $259.15M | $62.11M | $480.20M |
| Total liabilities | $262.35M | $697.32M | $28.52M | $210.17M |
| Shareholders' equity | $502.64M | -$438.17M | $33.59M | $139.07M |
| Return on year-end equity | 15.6% | n/a | 15.1% | -141.3% |
| Shares outstanding | 49.85M | 71.42M | 12.52M | 67.21M |
Revenue, most recent five fiscal years
| Fiscal year | Cryoport, Inc. | Phathom Pharmaceuticals, Inc. | Lifevantage Corp | Rhythm Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $176.18M Ended 2025-12-31 | $175.11M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $189.76M Ended 2025-12-31 |
| 1 year earlier | $156.77M Ended 2024-12-31 | $55.25M Ended 2024-12-31 | $228.53M Ended 2025-06-30 | $130.13M Ended 2024-12-31 |
| 2 years earlier | $168.66M Ended 2023-12-31 | $682.0K Ended 2023-12-31 | $200.16M Ended 2024-06-30 | $77.43M Ended 2023-12-31 |
| 3 years earlier | $237.28M Ended 2022-12-31 | $0 Ended 2022-12-31 | $213.40M Ended 2023-06-30 | $23.64M Ended 2022-12-31 |
| 4 years earlier | $222.61M Ended 2021-12-31 | n/a | $206.36M Ended 2022-06-30 | $3.15M Ended 2021-12-31 |